{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:00:33Z","timestamp":1790838033157,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the association between the nerve\u2010sparing (NS) technique applied during radical prostatectomy (RP) and early oncological and continence outcomes in patients with Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)\u2010defined high\u2010risk prostate cancer (PCa) undergoing robot\u2010assisted RP (RARP) within a structured patient\u2010specific surgical planning (PSSP) pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A retrospective single\u2010centre cohort study of 1385 patients who underwent primary RARP between 2021 and 2022 was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Patients were stratified into three groups according to the number of STAMPEDE\u2010defined high\u2010risk factors: none, one, and two or more. Outcomes were compared across these cohorts and between NS\u2010 and non\u2010NS (nNS)\u2010 RARP, within each risk stratum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, NS\u2010RARP was performed in 75.4% of patients (1044\/1385). In the STAMPEDE\u2010defined high\u2010risk cohort (two or more high\u2010risk criteria) 57.3% (150\/262) of patients underwent some sort of NS. Among those with at least two STAMPEDE\u2010defined risk factors, oncological outcomes were similar between NS and nNS surgery (positive surgical margin rate 21.3% vs 23.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.72; 12\u2010month biochemical recurrence rate 6.7% vs 5.4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.9), and urinary continence rates at 3 and 12\u2009months were also similar (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.2 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.5, respectively). However, high\u2010risk patients undergoing NS\u2010RARP used significantly fewer pads at 12\u2009months (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a contemporary RARP cohort within a PSSP pathway, NS was feasible in over half of high\u2010risk patients and was not associated with worse short\u2010term oncological outcomes. Although pad\u2010free continence rates were similar between NS and nNS groups, patients undergoing NS\u2010RARP used significantly fewer pads at 12\u2009months, suggesting a potential functional benefit that warrants further prospective evaluation of NS strategies in selected cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70460","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:45:46Z","timestamp":1790837146000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological and continence outcomes after nerve\u2010sparing robot\u2010assisted radical prostatectomy in selected\n                    <scp>STAMPEDE\u2010defined<\/scp>\n                    high\u2010risk prostate cancer"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2429-2688","authenticated-orcid":false,"given":"Andreia","family":"Bil\u00e9\u2010Silva","sequence":"first","affiliation":[{"name":"Department of Targeted Intervention University College London  London UK"},{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"},{"name":"Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-9878","authenticated-orcid":false,"given":"Prabhakar","family":"Rajan","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention University College London  London UK"},{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"},{"name":"Department of Urology Barts Health NHS Trust  London UK"},{"name":"Centre for Cancer Cell and Molecular Biology Barts Cancer Institute, Queen Mary University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Urology Barts Health NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-093X","authenticated-orcid":false,"given":"Mehmet","family":"\u00d6zalevli","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Department of Radiology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-1213","authenticated-orcid":false,"given":"Justin","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Kelkar","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Nathan","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-2100","authenticated-orcid":false,"given":"Greg","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Sooriakumaran","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-4822","authenticated-orcid":false,"given":"Ashwin","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Tandogdu","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention University College London  London UK"},{"name":"Department of Urology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.euo.2024.05.016","article-title":"Effect of radical prostatectomy on survival for men with high\u2010risk nonmetastatic prostate cancer features selected according to STAMPEDE criteria: an EMPaCT study","volume":"7","author":"Milonas D","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010ISUP\u2010SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford P","year":"2024","journal-title":"Eur Urol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high\u2010risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris L","year":"2020","journal-title":"Eur Urol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"e2115312","DOI":"10.1001\/jamanetworkopen.2021.15312","article-title":"Comparison of multimodal therapies and outcomes among patients with high\u2010risk prostate cancer with adverse Clinicopathologic features","volume":"4","author":"Kishan AU","year":"2021","journal-title":"JAMA Netw Open"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/bmj.g1502","article-title":"Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","volume":"348","author":"Sooriakumaran P","year":"2014","journal-title":"BMJ"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS\u2010RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker CC","year":"2020","journal-title":"The Lancet"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long\u2010term outcomes in the RADICALS\u2010RT trial (NCT00541047)","volume":"35","author":"Parker CC","year":"2024","journal-title":"Ann Oncol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non\u2010inferiority trial","volume":"21","author":"Kneebone A","year":"2020","journal-title":"Lancet Oncol"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2015.02.028","article-title":"Achieving quality Assurance of Prostate Cancer Surgery during Reorganisation of cancer services","volume":"68","author":"Cathcart P","year":"2015","journal-title":"Eur Urol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.12.008"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051057","article-title":"Negative mpMRI rules out extra\u2010prostatic extension in prostate cancer before robot\u2010assisted radical prostatectomy","volume":"12","author":"Dinneen E","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/diagnostics14080803","article-title":"Long\u2010term oncological outcomes after nerve\u2010sparing robot\u2010assisted radical prostatectomy for high\u2010risk localized prostate cancer: a single\u2010center, two\u2010arm prospective study","volume":"14","author":"Spirito L","year":"2024","journal-title":"Diagnostics"},{"key":"e_1_2_9_14_1","article-title":"Erectile function, urinary continence and oncologic outcomes of neurovascular bundle sparing robot\u2010assisted radical prostatectomy for high\u2010risk prostate cancer: a systematic review and meta\u2010analysis","volume":"13","author":"Liu Y","year":"2023","journal-title":"Front Oncol"},{"key":"e_1_2_9_15_1","first-page":"3896","article-title":"Clinical and oncological outcomes of robot\u2010assisted radical prostatectomy with nerve sparing vs. non\u2010nerve sparing for high\u2010risk prostate cancer cases","volume":"18","author":"Takahara K","year":"2019","journal-title":"Oncol Lett"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2022.04.013","article-title":"Characteristics of patients in SPCG\u201015\u2014a randomized trial comparing radical prostatectomy with primary radiotherapy plus androgen deprivation therapy in men with locally advanced prostate cancer","volume":"41","author":"Gongora M","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/03008880510030932","article-title":"Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens","volume":"39","author":"Epstein JI","year":"2005","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/modpathol.2010.155","article-title":"International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 5: surgical margins","volume":"24","author":"Tan PH","year":"2011","journal-title":"Mod Pathol"},{"key":"e_1_2_9_19_1","unstructured":"Definition of margin \u2013 NCI Dictionary of Cancer Terms \u2013 NCI. n.d.https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer\u2010terms\/def\/margin(accessed December 9 2025)"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","unstructured":"Von ElmE AltmanDG EggerMet\u00a0al.The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies2007;370:147","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00345-024-05262-0","article-title":"Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy \u2010 results from a contemporary National Cancer Database study","volume":"42","author":"Freitas PFS","year":"2024","journal-title":"World J Urol"},{"key":"e_1_2_9_22_1","unstructured":"EAU Guidelines Office.EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid Spain.2025"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","article-title":"Real\u2010world outcomes following biochemical recurrence after definitive therapy with a short prostate\u2010specific antigen doubling time: potential role of early secondary treatment","volume":"28","author":"Freedland SJ","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/EDBK_351033","article-title":"Best approaches and updates for prostate cancer biochemical recurrence","volume":"45","author":"Simon NI","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_9_25_1","first-page":"245","article-title":"Prostate cancer \u2010 major changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski MK","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.urolonc.2022.10.023","article-title":"The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression\u2010free survival: a will Rogers phenomenon","volume":"41","author":"Rakauskas A","year":"2023","journal-title":"Urol Oncol"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:45:51Z","timestamp":1790837151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":25,"alternative-id":["10.1111\/bju.70460"],"URL":"https:\/\/doi.org\/10.1111\/bju.70460","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70460"}}